OncoMatch/Clinical Trials/NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Is NCT04494503 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including APG-2575 and Rituximab for chronic lymphocytic leukemia.
Treatment: APG-2575 · Rituximab · Ibrutinib — The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 24 months
Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy within 24 months
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 months
autologous hematopoietic stem cell transplantation within 12 months
Cannot have received: adoptive cell immunotherapy
Exception: within 24 months
adoptive cell immunotherapy within 24 months
Cannot have received: monoclonal antibody therapy against CLL
Exception: within 4 weeks prior to the first dose of the study drug
Monoclonal antibody therapy against CLL was adopted within 4 weeks prior to the first dose of the study drug.
Cannot have received: anti-tumor therapies (chemotherapy, radiotherapy, anti-tumor steroid treatment, anti-tumor Chinese medicine treatment)
Exception: within 14 days or 5x half-life before the first dose of study drug
Receive any of the following treatments within 14 days or 5x half-life before the first dose of study drug, or clinically significant adverse reactions / toxicities due to previous treatments have not recovered to ≤ Grade 1: Anti-tumor therapies include chemotherapy, radiotherapy, anti-tumor steroid treatment, anti-tumor Chinese medicine treatment
Cannot have received: investigational treatment (including targeted small molecule drugs)
Exception: within 14 days or 5x half-life before the first dose of study drug
investigational treatment, including targeted small molecule drugs
Cannot have received: BCL2 inhibitor
Received Bcl-2 inhibitor treatment.
Lab requirements
Blood counts
Adequate bone marrow function independent of growth factor and transfusion
Kidney function
Adequate renal function
Liver function
Adequate liver function
Cardiac function
QTcF interval ≤450ms in males, and ≤470ms in females; Cardiovascular disease of grade ≥2 (New York Heart Association Class) excluded
QTcF interval ≤450ms in males, and ≤470ms in females. Adequate bone marrow function independent of growth factor and transfusion. Adequate renal and liver function. Cardiovascular disease of grade ≥2 (New York Heart Association Class) excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify